- Oops!Something went wrong.Please try again later.
The proposed acquisition values F-star at approximately $161 million.
Just a year ago, F-star priced its IPO at $7.
F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global oncology pipeline.
Four programs are progressing in the clinic, three based on F-star's tetravalent platform and one next-generation STING agonist, with multiple further undisclosed programs in development.
Leveraging its modular antibody technology, F-star has forged collaborations with major international biopharma companies across a wide range of therapeutic areas, including oncology, immunology, and neurology.
The invoX and F-star Board of Directors have unanimously approved the transaction. It is expected to close in 2H of 2022.
invoX, established in 2021 in the U.K., is Sino Biopharma's international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics.
Price Action: FSTX shares are up 67.1% at $6.65 during the premarket session on the last check Thursday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.